Neuroendocrine Tumors
Conditions
Keywords
beta- probe, radioguided surgery
Brief summary
Radioguided surgery (RGS) with beta- radioisotopes is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons. To validate this procedure, ex vivo specimens of tumours expressing somatostatin receptors, as small-intestine neuroendocrine (SI-NET), will be tested
Detailed description
Small Intestinal neuroendocrine patients, with a positive Ga-68-DOTATOC PET/CT, will receive a small amount of beta- radiopharmaceutical (Y-90-DOTATOC), and then operated, as clinical indicated. Tissue samples will be tested ex-vivo with a beta-probe prototype
Interventions
DRUGY90-DOTA-Tyr3-Octreotide
Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
Sponsors
European Institute of Oncology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* SI NET patients, Ga-68-DOTATOC PET/CT positive, proposed for surgery
Exclusion criteria
* negative PET/CT; pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of sensitivity of a beta- probe | 2 years | after receiving a small amount of radioactivity, patients will be operated and an evaluation of radioactivity on surgical specimens will be evaluated |
Countries
Italy
Outcome results
None listed